Marketdash
Back to News

Big Movers Monday: Jazz Pharma Surges on Cancer Trial Results While Markets Dip

MarketDash Editorial Team
20 days ago
Despite broader market weakness on Monday, several stocks posted impressive gains led by Jazz Pharmaceuticals' 18% jump on positive cancer trial data. Biotechs, lithium miners, and consumer brands rounded out the day's biggest winners.

The broader market wasn't having a great Monday, with the Dow Jones index dropping more than 100 points. But if you knew where to look, there were plenty of stocks defying gravity in a big way.

Leading the charge was Jazz Pharmaceuticals PLC (JAZZ), which rocketed 18% to $166.56 after dropping some impressive clinical trial news. The company announced top-line results from its Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. That's a mouthful, but it covers cancers of the stomach, gastroesophageal junction, and esophagus. When a biotech announces positive Phase 3 results for cancer treatments, investors tend to pay attention.

The Day's Biggest Winners

But Jazz wasn't alone in posting outsized gains. Here's the full roster of Monday's standout performers.

PACS Group, Inc. (PACS) absolutely exploded, jumping 49.5% to $15.82. The catalyst? The company announced it will release third-quarter results on November 19. That's a pretty remarkable reaction to an earnings date announcement, suggesting investors are expecting some very good news.

Sigma Lithium Corporation (SGML) gained 30.5% to $7.91, riding a wave of optimism about lithium demand. Ganfgeng Lithium Group's chairman issued bullish FY26 demand guidance, likely based on increased demand for batteries and power infrastructure. The stock may also be catching sympathy momentum from Chile's broader market rally, which makes sense given that Chile is the world's second-largest lithium producer.

Zymeworks Inc. (ZYME) rose 29.5% to $24.00 after the company and its partners reported statistically significant and clinically meaningful improvements across progression-free survival, overall survival, overall response rate, and duration of response in the HERIZON-GEA-01 study. That's the same trial that lifted Jazz Pharmaceuticals, highlighting how multiple companies can benefit from collaborative research efforts.

Invivyd, Inc. (IVVD) gained 27% to $2.9898, while Diginex Ltd (DGNX) rose 26% to $13.27. Neither company provided specific catalysts for the moves.

Nuvalent Inc (NUVL) surged 16.5% to $112.44 after announcing positive topline pivotal data from its ALKOVE-1 clinical trial of Neladalkib for TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer. More good news in the biotech space.

Jade Biosciences Inc (JBIO) rose 16.3% to $12.44, continuing the biotech momentum without a specific news catalyst.

Alto Neuroscience Inc (ANRO) gained 15.7% to $14.02 after BTIG analyst Thomas Shrader initiated coverage with a Buy rating and a $27 price target. That target implies significant upside from current levels, which explains the enthusiasm.

Mining and metals stocks also had a strong showing. Hycroft Mining Holding Corporation (HYMC) gained 14.6% to $10.38, while Trilogy Metals Inc (TMQ) rose 13.4% to $3.98. Both likely benefited from broader strength in commodities.

LB Pharmaceuticals Inc (LBRX) rose 13.1% to $16.86, and Grail Inc (GRAL) shares gained 12% to $89.20.

Quantum Computing Inc (QUBT) shares surged 11.3% to $11.78 after the company reported better-than-expected third-quarter financial results on Friday. Sometimes good news takes a day or two to fully sink in with investors.

WPP PLC (WPP) rose 11.2% to $21.11, posting solid gains for the advertising and marketing services giant.

More Notable Gainers

Figure Technology Solutions Inc (FIGR) gained 11.2% to $44.74 after getting some analyst love. Mizuho and B of A Securities both raised their price targets on the stock, signaling increased confidence in the fintech company's prospects.

Dyne Therapeutics Inc (DYN) surged 10.5% to $20.76, while Terns Pharmaceuticals Inc (TERN) rose 9.6% to $24.74, both adding to the day's biotech strength.

Vita Coco Company Inc (COCO) shares jumped 9.1% to $47.84 after B of A Securities analyst Bryan Spillane upgraded the coconut water maker from Neutral to Buy and raised the price target from $48 to $54. When an analyst upgrades a stock and raises the target above the current price, it tends to get investors' attention.

Brinker International Inc (EAT) gained 8.3% to $122.55, showing continued strength in the restaurant sector.

Albemarle Corp (ALB) rose 7.6% to $123.88, likely benefiting from the same lithium industry optimism that lifted Sigma Lithium earlier in the session.

Finally, Crocs Inc (CROX) gained 4.9% to $76.95 after the company promoted Rupert Campbell to EVP and President of HEYDUDE from SVP and Chief Commercial Officer. The leadership move signals confidence in the HEYDUDE brand's continued growth trajectory.

While the broader market struggled to find its footing on Monday, these stocks showed that individual company news and sector-specific catalysts can still drive impressive gains. Whether it's breakthrough clinical trial data, bullish analyst calls, or positive industry trends, there's always action somewhere in the market.

Back to News

Big Movers Monday: Jazz Pharma Surges on Cancer Trial Results While Markets Dip

MarketDash Editorial Team
20 days ago
Despite broader market weakness on Monday, several stocks posted impressive gains led by Jazz Pharmaceuticals' 18% jump on positive cancer trial data. Biotechs, lithium miners, and consumer brands rounded out the day's biggest winners.

The broader market wasn't having a great Monday, with the Dow Jones index dropping more than 100 points. But if you knew where to look, there were plenty of stocks defying gravity in a big way.

Leading the charge was Jazz Pharmaceuticals PLC (JAZZ), which rocketed 18% to $166.56 after dropping some impressive clinical trial news. The company announced top-line results from its Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. That's a mouthful, but it covers cancers of the stomach, gastroesophageal junction, and esophagus. When a biotech announces positive Phase 3 results for cancer treatments, investors tend to pay attention.

The Day's Biggest Winners

But Jazz wasn't alone in posting outsized gains. Here's the full roster of Monday's standout performers.

PACS Group, Inc. (PACS) absolutely exploded, jumping 49.5% to $15.82. The catalyst? The company announced it will release third-quarter results on November 19. That's a pretty remarkable reaction to an earnings date announcement, suggesting investors are expecting some very good news.

Sigma Lithium Corporation (SGML) gained 30.5% to $7.91, riding a wave of optimism about lithium demand. Ganfgeng Lithium Group's chairman issued bullish FY26 demand guidance, likely based on increased demand for batteries and power infrastructure. The stock may also be catching sympathy momentum from Chile's broader market rally, which makes sense given that Chile is the world's second-largest lithium producer.

Zymeworks Inc. (ZYME) rose 29.5% to $24.00 after the company and its partners reported statistically significant and clinically meaningful improvements across progression-free survival, overall survival, overall response rate, and duration of response in the HERIZON-GEA-01 study. That's the same trial that lifted Jazz Pharmaceuticals, highlighting how multiple companies can benefit from collaborative research efforts.

Invivyd, Inc. (IVVD) gained 27% to $2.9898, while Diginex Ltd (DGNX) rose 26% to $13.27. Neither company provided specific catalysts for the moves.

Nuvalent Inc (NUVL) surged 16.5% to $112.44 after announcing positive topline pivotal data from its ALKOVE-1 clinical trial of Neladalkib for TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer. More good news in the biotech space.

Jade Biosciences Inc (JBIO) rose 16.3% to $12.44, continuing the biotech momentum without a specific news catalyst.

Alto Neuroscience Inc (ANRO) gained 15.7% to $14.02 after BTIG analyst Thomas Shrader initiated coverage with a Buy rating and a $27 price target. That target implies significant upside from current levels, which explains the enthusiasm.

Mining and metals stocks also had a strong showing. Hycroft Mining Holding Corporation (HYMC) gained 14.6% to $10.38, while Trilogy Metals Inc (TMQ) rose 13.4% to $3.98. Both likely benefited from broader strength in commodities.

LB Pharmaceuticals Inc (LBRX) rose 13.1% to $16.86, and Grail Inc (GRAL) shares gained 12% to $89.20.

Quantum Computing Inc (QUBT) shares surged 11.3% to $11.78 after the company reported better-than-expected third-quarter financial results on Friday. Sometimes good news takes a day or two to fully sink in with investors.

WPP PLC (WPP) rose 11.2% to $21.11, posting solid gains for the advertising and marketing services giant.

More Notable Gainers

Figure Technology Solutions Inc (FIGR) gained 11.2% to $44.74 after getting some analyst love. Mizuho and B of A Securities both raised their price targets on the stock, signaling increased confidence in the fintech company's prospects.

Dyne Therapeutics Inc (DYN) surged 10.5% to $20.76, while Terns Pharmaceuticals Inc (TERN) rose 9.6% to $24.74, both adding to the day's biotech strength.

Vita Coco Company Inc (COCO) shares jumped 9.1% to $47.84 after B of A Securities analyst Bryan Spillane upgraded the coconut water maker from Neutral to Buy and raised the price target from $48 to $54. When an analyst upgrades a stock and raises the target above the current price, it tends to get investors' attention.

Brinker International Inc (EAT) gained 8.3% to $122.55, showing continued strength in the restaurant sector.

Albemarle Corp (ALB) rose 7.6% to $123.88, likely benefiting from the same lithium industry optimism that lifted Sigma Lithium earlier in the session.

Finally, Crocs Inc (CROX) gained 4.9% to $76.95 after the company promoted Rupert Campbell to EVP and President of HEYDUDE from SVP and Chief Commercial Officer. The leadership move signals confidence in the HEYDUDE brand's continued growth trajectory.

While the broader market struggled to find its footing on Monday, these stocks showed that individual company news and sector-specific catalysts can still drive impressive gains. Whether it's breakthrough clinical trial data, bullish analyst calls, or positive industry trends, there's always action somewhere in the market.